Abstract
Melanoma causes more than 75% of all skin cancer deaths with an estimated 44,000 new cases of melanoma in the United States in the year 2000. Melanoma exhibits the highest FDG uptake of all malignancies. FDG-PET is therefore used to stage and restage the disease. Treatment options are limited in melanoma. However, the molecular information provided by PET is of particular importance if experimental treatments are contemplated or if surgery for removing “isolated” metastases is considered.
No data are thus far available to determine the additional value of PET/CT over PET alone.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Suggested Reading
Steinert HC, Huch Böni RA, Buck A, Böni R, Berthold T, Marincek B, Burg G, von Schulthess GK. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1995;195(3):705–709.
Macfarlane DJ, Sondak V, Johnson T, Wahl RL. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol. 1998;16(5):1770–1776.
Rinne D, Baum RP, Hör G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer. 1998;82(9):1664–1671.
Eigtved A, Andersson AP, Dahlstrom K, Rabol A, Jensen M, Holm S, Sorensen SS, Drzewiecki KT, Hojgaard L, Friberg L. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med. 2000;27(1):70–75.
Jadvar H, Johnson DL, Segall GM. The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma. Clin Nucl Med. 2000;25(1):48–51.
Schwimmer J, Essner R, Patel A, Jahan SA, Shepherd JE, Park K, Phelps ME, Czernin J, Gambhir SS. A review of the literature for whole-body FDG PET in the management of patients with melanoma. Q J Nucl Med. 2000;44(2): 153–167.
Crippa F, Leutner M, Belli F, Gallino F, Greco M, Pilotti S, Cascinelli N, Bombardieri E. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med. 2000;41(9): 1491–1494.
Wong C, Silverman DH, Seltzer M, Schiepers C, Ariannejad M, Gambhir SS, Phelps ME, Rao J, Valk P, Czernin J. The Impact of 2-deoxy-2[18F] fluoro-D-glucose whole body positron emission tomography for managing patients with melanoma: the referring physician’s perspective. Mol Imaging Biol. 2002;4(2): 185–190.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Czernin, J., Dahlbom, M., Ratib, O., Schiepers, C. (2004). Cancers of the Skin. In: Atlas of PET/CT Imaging in Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18517-5_16
Download citation
DOI: https://doi.org/10.1007/978-3-642-18517-5_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62141-3
Online ISBN: 978-3-642-18517-5
eBook Packages: Springer Book Archive